Roche AG

Roche AG
Grenzacherstrasse 124, 4070 Basel, Switzerland
Roche AG  
Discipline: Pharmacology
Pharmacology - Health - Nov 11
Roche today announced data from the phase II NOBILITY study, investigating the safety and efficacy of Gazyva (obinutuzumab) for adults with proliferative lupus nephritis. 1 The study met the primary endpoint with Gazyva, in combination with standard of care (mycophenolate mofetil or mycophenolic acid and corticosteroids), demonstrating superiority compared to placebo plus standard of care.
Pharmacology - Life Sciences - Nov 11

Roche today announced positive data from the pivotal Part 2 of SUNFISH, a study evaluating risdiplam in people aged 2-25 years with Type 2 or 3 spinal muscular atrophy (SMA). The study met its primary endpoint of change from baseline in the Motor Function Measure 32 (MFM-32) scale after one year of treatment with risdiplam, compared to placebo.

Pharmacology - Health - Oct 30

Satralizumab represents a potential new approach to treating neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating disease often misdiagnosed as multiple sclerosis European Medicines Agency (EMA) grants Accelerated Assessment for satralizumab application Roche announced today that

Health - Pharmacology - Oct 18

Single-dose Xofluza is the first and only antiviral medicine indicated specifically for patients at high risk of developing serious complications from influenza (flu) The Centers for Disease Control and Prevention (CDC) defines people at high risk of serious flu complications as those who have co

Pharmacology - Health - Sep 30

Roche presents positive Phase III results for Tecentriq (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer.

Pharmacology - Health - Sep 30

Rituxan is the first and only FDA-approved treatment for paediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis These two forms of vasculitis in children are rare and associated with severe, potentially life-threatening symptoms This

Pharmacology - Health - Sep 27

Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression live longer compared with chemotherapy alone Data will be shared with health authorities globally, including the US Food and Drug Administration (FDA)

Pharmacology - Health - Nov 6

Ten Roche medicines will be featured in more than 70 abstracts and 21 oral presentations, across a range of 15 blood cancers and non-malignant haematological conditions New data for CD20-CD3 bispecific cancer immunotherapies confirms their potential in difficult-to-treat lymphomas Long-term data

Pharmacology - Health - Oct 21

First Phase III cancer immunotherapy study to show an improvement in overall survival and progression-free survival for the treatment of the most common form of liver cancer Data will be submitted to health authorities globally, including the U.S. Food and Drug Administration, the E

Pharmacology - Health - Oct 14

Phase III PEMPHIX study shows Roche's MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris.

Health - Pharmacology - Sep 30

Efficacy of Alecensa (alectinib) in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with efficacy in those identified by tissue analysis in the pivotal Phase III ALEX study Roche will today announce positive results from a single-arm cohort of t

Pharmacology - Health - Sep 28

New real-world data from the Flatiron database supports clinical benefits of Alecensa (alectinib) across time to treatment discontinuation, real-world progression free survival and overall survival Final PFS and updated data from the pivotal Phase III ALEX study reinforces efficacy of Alecensa in

Pharmacology - Health - Sep 27

The study showed a confirmed objective response rate of 36% for people treated with the Tecentriq and Avastin combination in unresectable hepatocellular carcinoma who have not received prior systemic therapy The combination of Tecentriq and Avastin was shown to reduce the risk of disease worsenin





website preview

Link

Medicine and Life Sciences

This site uses cookies and analysis tools to improve the usability of the site. More information. |